Butterfly Network (BFLY) stock jumps as Midjourney unveils full-body ultrasound scanner

Butterfly Network, Inc. (NYSE: BFLY) shares surged 55.9% to close at $8.90 after Midjourney disclosed that its proposed full-body ultrasound scanner uses Butterfly Network’s semiconductor imaging technology. The prototype contains 40 Butterfly Ultrasound-on-Chip modules, with future versions expected to require substantially more components. Butterfly Network already has a five-year co-development and licensing agreement with Midjourney that includes up to $74 million in fixed and milestone payments, alongside potential chip sales and commercial revenue sharing. The announcement transforms a previously disclosed contract into a visible product opportunity that investors can assess more directly. However, the valuation now assumes significant progress from a scanner that remains precommercial, lacks diagnostic clearance and faces unresolved clinical questions.

Midjourney Medical plans to develop a water-based scanner that can produce a three-dimensional map of the body in approximately 60 seconds. A person would be lowered through a ring of ultrasound sensors, generating large volumes of data that are reconstructed into internal images using high-performance computing and segmentation software. Midjourney intends to open an initial research spa in San Francisco by the end of 2027 before expanding to additional cities and potentially seeking regulatory clearance for broader medical uses.

The scale of the market response reflects more than curiosity about an artificial intelligence company entering healthcare. Butterfly Network shares closed only four cents below their new 52-week high of $8.94, after trading as low as $1.32 during the previous year. The stock gained approximately 56.7% across five trading sessions and about 131.8% over one month, creating one of the sharpest healthcare technology reratings in the small-cap market.

Why did Butterfly Network shares surge after Midjourney revealed its medical scanner?

The immediate catalyst was the first detailed public explanation of how Midjourney intends to use Butterfly Network’s ultrasound technology. Investors already knew that the two companies had signed a material agreement in November 2025, but the original filing disclosed little about the product, target market or likely hardware requirements. The scanner announcement filled part of that information gap by showing that Butterfly Network is not merely providing software access or research support.

Each current-generation scanner incorporates 40 Butterfly Ultrasound-on-Chip modules. Future generations are expected to require considerably more modules, potentially increasing Butterfly Network’s hardware exposure if Midjourney progresses from prototypes to commercial production. That component intensity is important because the economic opportunity may ultimately extend beyond licensing fees into recurring chip supply and revenue-sharing income.

The announcement also validates Butterfly Network’s effort to position its semiconductor technology as a platform rather than a single handheld ultrasound product. The company historically built its investment case around portable point-of-care imaging, but its Butterfly Embedded business now licenses imaging hardware and software to third parties developing new applications. Midjourney provides the most visible demonstration yet of how that embedded strategy could open markets outside conventional hospital ultrasound.

The share-price reaction nevertheless contained a considerable speculative element. Midjourney has not disclosed a commercial scanner price, manufacturing budget, reimbursement strategy or detailed clinical development programme. The market has therefore priced a long-term technology vision more quickly than the operating evidence has developed.

What does the Midjourney scanner reveal about Butterfly Network’s embedded strategy?

Butterfly Network’s central technology replaces many components used in traditional ultrasound machines with a semiconductor-based imaging system. This architecture allows the company to place ultrasound capabilities into compact hardware while updating imaging performance through software and computing improvements. The same architecture can potentially be licensed to partners that require imaging or sensing technology but do not want to build ultrasound components independently.

The Midjourney agreement demonstrates how Butterfly Network can earn revenue without carrying the entire cost of developing, marketing and distributing every end product. Midjourney is responsible for designing the scanner experience, building the surrounding consumer concept and attempting to establish a commercial market. Butterfly Network supplies licensed technology, development support and potentially a significant quantity of imaging modules.

That division of responsibilities can improve capital efficiency. Butterfly Network gains exposure to a potentially large market while limiting its direct spending on spas, consumer acquisition and full-body scanner manufacturing. If the product fails, Butterfly Network still receives contractual licensing income during the agreement, subject to the contract remaining in force and development obligations being satisfied.

The embedded model also introduces concentration risk. A growing portion of high-margin revenue could become dependent on a relatively small group of development partners whose commercial timelines remain outside Butterfly Network’s control. Midjourney’s financial resources, product priorities and willingness to continue funding a regulated healthcare project will therefore matter to Butterfly Network investors even though Midjourney is privately held.

How financially important could the $74 million agreement become for Butterfly Network?

The agreement includes a $15 million non-recurring payment and annual licence payments of $10 million during its five-year term. Midjourney can also pay up to $9 million when specified development milestones are achieved. These amounts produce the disclosed figure of up to $74 million before considering potential revenue-sharing payments and purchases of Butterfly Network chips.

The contract is significant relative to Butterfly Network’s existing scale. The company generated $26.5 million of revenue in the first quarter of 2026, representing 25% year-on-year growth. Butterfly Network has forecast full-year revenue of between $117 million and $121 million, meaning the annual Midjourney licence payment alone is equivalent to roughly 8% of the midpoint of current guidance.

The commercial impact is already visible in Butterfly Network’s financial results. The Midjourney relationship contributed to United States revenue growth during the first quarter, while the embedded business helped lift gross margin to 68.9% from 63% a year earlier. Licensing income typically carries higher margins than manufacturing and selling physical ultrasound probes, giving the partnership strategic importance beyond its absolute revenue contribution.

Butterfly Network is still loss-making. The company reported a first-quarter net loss of $12.7 million and an adjusted EBITDA loss of $6.1 million, although both measures improved from the previous year. Cash and cash equivalents stood at $138 million at the end of March, providing a meaningful buffer while management invests in embedded partnerships, software, international expansion and new semiconductor architecture.

The contract does not guarantee that all expected revenue will be realised. Milestone payments depend on development progress, while chip purchases and revenue sharing require Midjourney to reach commercial production. Contract termination, renegotiation or product delays could reduce the opportunity that investors are currently capitalising into Butterfly Network’s share price.

Can a 60-second full-body ultrasound scanner compete with MRI and conventional imaging?

Midjourney’s proposition is based on the idea that ultrasound can become faster, less expensive and more accessible when paired with large sensor arrays and substantial computing power. The scanner uses no ionising radiation and does not require the powerful magnets associated with magnetic resonance imaging. This could make the technology suitable for frequent body-composition monitoring if image quality, safety and operating costs meet commercial expectations.

The product should not yet be treated as a substitute for magnetic resonance imaging, computed tomography or conventional diagnostic ultrasound. Different imaging modalities reveal different structures, tissues and disease processes. Ultrasound can struggle with bone, air-filled organs and certain deep structures, while magnetic resonance imaging remains highly valuable for neurological, musculoskeletal and soft-tissue assessment.

Midjourney plans to begin with detailed body-composition maps rather than diagnostic claims. That is a strategically sensible entry point because wellness and composition applications may face a different regulatory threshold from products intended to detect or diagnose disease. It also allows the company to gather operating experience while refining reconstruction algorithms and future hardware generations.

The commercial opportunity could still be meaningful even if the scanner never replaces established imaging systems. A fast tool that measures changes in muscle, fat and organ composition may appeal to preventive health providers, performance clinics and consumers interested in longitudinal health tracking. The risk is that an attractive visual experience becomes confused with clinically validated diagnosis, which could expose both Midjourney and its technology suppliers to reputational pressure.

What regulatory and clinical risks could delay the Midjourney Medical commercial roadmap?

Midjourney expects to submit test results to the United States Food and Drug Administration as it seeks permission to expand the scanner’s capabilities. The regulatory pathway will depend on the claims Midjourney makes, the intended users, the clinical decisions influenced by the data and whether comparable legally marketed devices exist. A wellness body-composition service could reach customers before a diagnostic system, but that would limit the product’s initial medical utility.

Clinical validation will be a larger challenge than producing visually impressive scan reconstructions. Midjourney will need evidence that the scanner accurately measures the structures it claims to identify, produces consistent results across different body types and offers information that improves patient or consumer decisions. Speed is valuable, but speed without sufficient sensitivity, specificity and repeatability merely produces uncertainty more efficiently.

Frequent full-body imaging may also create incidental findings. Detecting ambiguous abnormalities can lead to anxiety, follow-up testing and procedures that may not improve outcomes. A business model encouraging weekly or monthly scanning will therefore attract scrutiny over whether additional data produces better health decisions or simply more medical activity.

Data governance is another unresolved issue. Whole-body scans could become among the most sensitive categories of consumer health information, particularly if combined with behavioural, genetic or longitudinal data. Midjourney will need clear policies covering consent, storage, artificial intelligence training, data sharing and access by clinicians or third-party health applications.

Manufacturing presents an additional execution risk for Butterfly Network. Supplying dozens or potentially hundreds of imaging modules per scanner would require consistent quality, reliable yields and adequate production capacity. A product designed for continuous consumer use would also need durability and service standards that differ from a research prototype.

Does Butterfly Network’s current valuation already price in too much Midjourney success?

At $8.90 per share, Butterfly Network had a market capitalisation of approximately $2.3 billion. That valuation is close to 20 times the midpoint of the company’s 2026 revenue guidance, a demanding multiple for a business that remains unprofitable and expects an adjusted EBITDA loss of between $21 million and $25 million this year. Investors are therefore valuing Butterfly Network as an emerging medical-imaging platform rather than a conventional device manufacturer.

The market’s optimism is not based entirely on the Midjourney announcement. Butterfly Network’s first-quarter revenue increased 25%, gross margin expanded by nearly six percentage points and its adjusted EBITDA loss narrowed from $9.1 million to $6.1 million. The company is also expanding its iQ3 handheld ultrasound business, artificial intelligence applications, home-care strategy and partnerships within Butterfly Embedded.

However, the latest price has moved above the average of several published analyst targets. Available target estimates extend from approximately $5.25 to $11, with the average near $7. This suggests that the stock has rerated faster than analysts have updated their financial models, although target prices may change following the Midjourney disclosure.

The five-day and one-month advances also indicate elevated retail-investor interest. Trading volume reached roughly 60 million shares during the surge, about ten times the recent average. That liquidity can support further momentum, but it also increases the possibility of sharp reversals when traders take profits or seek additional evidence.

The most balanced interpretation is that Butterfly Network has gained a credible new growth option, but not yet a proven commercial imaging franchise. The agreement generates real revenue and provides validation of the embedded model. The scanner’s long-term value, however, depends on Midjourney converting a technically ambitious prototype into a regulated, manufactured and widely used product.

What should BFLY investors watch before the next Butterfly Network earnings update?

The first issue will be whether management changes its 2026 guidance. Butterfly Network previously forecast revenue of $117 million to $121 million, and investors will examine whether Midjourney’s development pace creates additional revenue beyond amounts already included. Guidance that remains unchanged would not invalidate the opportunity, but it could remind the market that most commercial upside lies beyond the current year.

Investors should also track the composition of revenue. Embedded licensing can raise gross margins and reduce dependence on probe sales, but the company must disclose enough information for shareholders to understand recurring income, milestone revenue and partner concentration. Growth driven by one-time development payments should not receive the same valuation as repeatable software or chip revenue.

Midjourney’s next technical disclosures will matter almost as much as Butterfly Network’s financial results. Research-trial data, second-generation hardware specifications and progress on the San Francisco site could indicate whether the project is moving from demonstration to deployment. Delays, design changes or reduced module requirements would alter the expected economics for Butterfly Network.

Management must also show that enthusiasm around Midjourney does not distract from the core point-of-care ultrasound business. Sustainable value will depend on hospitals, clinicians and community-care providers continuing to adopt Butterfly Network products while the embedded portfolio develops. A single spectacular partner can attract attention, but a diversified group of paying customers is what turns a platform story into a durable company.

The Midjourney disclosure represents genuine strategic validation for Butterfly Network, particularly because the relationship is governed by a material paid agreement rather than an informal pilot. The market is also correct to recognise that higher module requirements could expand the contract beyond licence income. Yet the share-price surge has compressed the margin for error, leaving investors exposed to regulatory delays, prototype setbacks and any evidence that the scanner’s clinical usefulness falls short of its visual ambition.

What are the key takeaways from Butterfly Network’s Midjourney scanner partnership?

• Butterfly Network shares closed at $8.90 after gaining 55.9% in one session and approximately 56.7% across five trading days.
• BFLY stock has risen about 131.8% over one month and is trading near its $8.94 52-week high.
• Midjourney’s current scanner prototype uses 40 Butterfly Ultrasound-on-Chip modules, with future versions expected to require more components.
• The five-year agreement includes up to $74 million in fixed and milestone payments, plus possible chip sales and commercial revenue sharing.
• The partnership validates Butterfly Network’s strategy of licensing its imaging technology beyond handheld medical ultrasound.
• Butterfly Network’s high-margin embedded revenue is already supporting revenue growth and gross-margin expansion.
• Midjourney’s scanner remains a prototype and does not yet have clearance for diagnostic medical use.
• Clinical validation, incidental findings, data governance and manufacturing scale are major execution risks.
• Butterfly Network’s approximately $2.3 billion valuation is close to 20 times the midpoint of 2026 revenue guidance.
• Further gains will depend on measurable development milestones rather than continued excitement around the scanner concept alone.